Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.69 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.69 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.69 |
| ▸ | TGM2 | P21980 | 1/20 | 0.64 |
| ▸ | IMPDH2 | P12268 | 6/20 | 0.64 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.64 |
| ▸ | RNASEL | Q05823 | 2/20 | 0.61 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23752167 | 0.93 | TGM2 (0.70) | NT5ETAS1R3TAS1R1TGM2RNASEL | |
| SCHEMBL29258512 | 0.93 | NT5E (0.69) | NT5ETAS1R3TAS1R1TGM2IMPDH2 | |
| SCHEMBL2315499 | 0.93 | NT5E (0.69) | NT5ETAS1R3TAS1R1TGM2IMPDH2 | |
| SCHEMBL17586739 | 0.93 | NT5E (0.69) | NT5ETAS1R3TAS1R1TGM2IMPDH2 | |
| SCHEMBL3178906 | 0.93 | NT5E (0.64) | NT5ETAS1R3TAS1R1TGM2IMPDH2 | |
| SCHEMBL12714573 | 0.92 | NT5E (0.82) | NT5ETAS1R3TAS1R1TGM2 | |
| SCHEMBL31310507 | 0.92 | TAS1R3 (0.67) | NT5ETAS1R3TAS1R1TGM2IMPDH2 | |
| SCHEMBL1620396 | 0.92 | TGM2 (0.69) | NT5ETAS1R3TAS1R1TGM2RNASEL | |
| SCHEMBL1620402 | 0.92 | TGM2 (0.69) | NT5ETAS1R3TAS1R1TGM2RNASEL | |
| SCHEMBL720437 | 0.92 | TAS1R3 (0.70) | NT5ETAS1R3TAS1R1TGM2IMPDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110189664-A1 | DIAGNOSTICS IN A MONOPLEX/MULTIPLEX FORMAT | UNIVERSITY OF WOLLONGONG | 2011-08-04 | — | — | US | disclosed |
| US-20090286696-A1 | Double-Stranded Olidonucleotides and Uses Therefor | UNIVERSITY OF WOLLONGONG | 2009-11-19 | — | — | US | disclosed |
| WO-2008148143-A1 | DIAGNOSTICS IN A MONOPLEX/MULTIPLEX FORMAT | UNIVERSITY OF WOLLONGONG (AU) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286696-A1 | Double-Stranded Olidonucleotides and Uses Therefor | DNTT, ADAR, DUT | NT5E 34/4885TAS1R3 1109/4885TAS1R1 1445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.